MUC1 Peptide Vaccine
Phase 1Vaccine
MUC1 Peptide Vaccine is one of 9 biologic programs targeting Ductal Carcinoma in Situ. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Ductal Carcinoma in Situ
#DrugCompanyPhaseTrials
1Orserdu
SStemline Therapeutics, Inc.
Phase 2
Keytruda
Merck & Co.Phase 1
Z-Endoxifen
AAtossa Therapeutics, Inc.
Phase 2
Aromatase Inhibitor
PfizerPhase 1
Hiltonol
PPCI Biotech AS
Phase 1
CAN1012
CCanwell Biotech Limited
Phase 1
Pegylated IFN-Alpha 2b
GGynecologic Oncology Group
Preclinical
MUC1 Peptide Vaccine
FFinn, Olivera, PhD
Phase 1
Herceptin
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MUC1 Peptide Vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 1[1]
- Company
- FFinn, Olivera, PhD